Literature DB >> 23639855

Left ventricular function improvement after prophylactic implantable cardioverter-defibrillator implantation in patients with non-ischaemic dilated cardiomyopathy.

Wolfram Grimm1, Nina Timmesfeld, Elena Efimova.   

Abstract

AIMS: To assess the incidence and prognostic significance of left ventricular (LV) function improvement in patients with non-ischaemic dilated cardiomyopathy (DCM) and prophylactic implantable cardioverter-defibrillator (ICD). METHODS AND
RESULTS: A total of 123 patients with DCM and echocardiographic follow-up assessments within 1 year after prophylactic ICD implant were retrospectively studied at our institution. All patients had New York Heart Association class II or III symptoms in the presence of a LV ejection fraction of 23 ± 6% (range: 9-35%) despite optimized medical therapy for at least 3 months prior to ICD implant. Left ventricular function improvement was defined as an increase of LV ejection fraction of more than 5% to more than 35% combined with a decrease LV end-diastolic diameter of at least 5 mm. Left ventricular function improvement after prophylactic ICD implant was found in 30 of 123 patients (24%). Multivariate logistic regression revealed recent onset DCM with symptoms ≤9 months as the only significant predictor of LV function improvement [odds ratio: 6.89; 95% confidence interval (CI): 2.43-21.99, P = 0.0002]. During 74 months mean follow-up, total mortality was higher in patients without vs. with LV function improvement [hazard ratio (HR): 3.75; 95% CI: 1.14-12.31, P = 0.0034], while the incidence of appropriate ICD therapies was similar in both groups in the early phase after prophylactic ICD implant (HR: 1.15; 95% CI: 0.57-2.33, P = 0.70). The incidence of appropriate ICD therapies decreased to ∼1% per year after LV function improvement had occurred.
CONCLUSION: Recently diagnosed DCM predicts LV function improvement after prophylactic ICD implant. Overall survival was significantly better in patients with vs. without LV function improvement, while appropriate ICD therapy rates were similar in both groups in the early phase after prophylactic ICD implantation before LV function improvement occurred.

Entities:  

Keywords:  Implantable cardioverter-defibrillator; Left ventricular function improvement

Mesh:

Year:  2013        PMID: 23639855     DOI: 10.1093/europace/eut097

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  5 in total

1.  Risk of ventricular tachyarrhythmias following improvement of left ventricular ejection fraction in patients with implantable cardiac defibrillators implanted for primary prevention of sudden cardiac death.

Authors:  Jayasree Pillarisetti; Rakesh Gopinathannair; Matthew J Haney; Bassem Abazid; Wasiq Rawasia; Madhu Yeruva Reddy; Niveditha Adabala; Sudharani Bommana; Martin Emert; Dhanunjaya Lakkireddy
Journal:  J Interv Card Electrophysiol       Date:  2017-02-01       Impact factor: 1.900

Review 2.  Value of The Wearable Cardioverter Defibrillator (WCD) as a Bridging-Therapy before Implantation of a Cardioverter Defibrillator (ICD).

Authors:  Priv Doz; Johannes Sperzel
Journal:  J Atr Fibrillation       Date:  2016-02-29

3.  Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study.

Authors:  David Duncker; Thorben König; Stephan Hohmann; Johann Bauersachs; Christian Veltmann
Journal:  J Am Heart Assoc       Date:  2017-01-17       Impact factor: 5.501

4.  Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.

Authors:  Susanne Röger; Stefanie L Rosenkaimer; Anna Hohneck; Siegfried Lang; Ibrahim El-Battrawy; Boris Rudic; Erol Tülümen; Ksenija Stach; Jürgen Kuschyk; Ibrahim Akin; Martin Borggrefe
Journal:  BMC Cardiovasc Disord       Date:  2018-03-15       Impact factor: 2.298

Review 5.  Role of the Wearable Defibrillator in Newly Diagnosed Heart Failure.

Authors:  David Duncker; Christian Veltmann
Journal:  Curr Heart Fail Rep       Date:  2018-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.